L3VLUP
ProSign in

BEAM · GILD in the 13F filings

Two to four stocks side by side among the 95 tracked managers: who lists them, how that has moved, who bought and sold in a quarter, and which managers hold more than one.

BEAMGILD
Quarter
Q2 2026Q1 2026Q4 2025Q3 2025Q2 2025Q1 2025Q4 2024Q3 2024Q2 2024Q1 2024Q4 2023

Holders over time

Tracked managers listing each stock every quarter, at least, or their combined reported value. A gap is a quarter in which no tracked manager listed it. Click a quarter to compare there.
  • BEAM
  • GILD
010203040202120222023202420252026
Holders and value by quarter
QuarterBEAMGILD
Q3 2020none listed holders, n.a.25 holders, $14.2bn
Q4 20204 holders, $705m27 holders, $13.4bn
Q1 20216 holders, $1.1bn24 holders, $14.5bn
Q2 20216 holders, $2.1bn18 holders, $14.9bn
Q3 20215 holders, $769m20 holders, $16.4bn
Q4 20213 holders, $818m20 holders, $16.8bn
Q1 20224 holders, $620m28 holders, $13.2bn
Q2 20224 holders, $457m26 holders, $13.6bn
Q3 20225 holders, $610m24 holders, $13.3bn
Q4 20224 holders, $481m32 holders, $21.1bn
Q1 20234 holders, $397m27 holders, $21.8bn
Q2 20233 holders, $394m24 holders, $20.7bn
Q3 20234 holders, $351m24 holders, $20.0bn
Q4 20234 holders, $389m22 holders, $21.5bn
Q1 20244 holders, $446m30 holders, $20.3bn
Q2 20243 holders, $379m28 holders, $18.5bn
Q3 20243 holders, $370m29 holders, $24.2bn
Q4 20244 holders, $394m28 holders, $25.9bn
Q1 20255 holders, $419m33 holders, $32.0bn
Q2 20255 holders, $358m27 holders, $30.9bn
Q3 20257 holders, $571m23 holders, $29.4bn
Q4 20256 holders, $692m25 holders, $34.3bn
Q1 20263 holders, $540m25 holders, $38.5bn
Q2 20263 holders, $713m26 holders, $34.2bn
BEAM

Beam Therapeutics Inc

Holders
5
Reported value
$358m
Buyers
4
Sellers
1

Breadth +3 among 95 comparable managers.

Pharmaceuticals and biotechnologyBiological productsHealthcare: biopharma and medtech · L3VLUP
GILD

Gilead Sciences Inc

Holders
27
Reported value
$30.9bn
Buyers
18
Sellers
10

Breadth +8 among 95 comparable managers.

Pharmaceuticals and biotechnologyBiological productsHealthcare: biopharma and medtech · L3VLUP

Who holds both, Q2 2025

Among the 31 tracked managers listing any of them. "Only" is about listed positions: a manager may hold the other below its listed range.

Only BEAM (4)

ARK Investment Management LLC, Baillie Gifford & Co, Farallon Capital Management LLC, Voloridge Investment Management LLC

Only GILD (26)

Acadian Asset Management LLC, AllianceBernstein LP, AQR Capital Management LLC, Arrowstreet Capital LP, Balyasny Asset Management LLC, Bridgewater Associates LP, Capital Research Global Investors, Capital World Investors, Citadel Advisors LLC, D. E. Shaw & Co., Dodge & Cox, Fidelity (FMR LLC), Holocene Advisors LP, Invesco Ltd, Janus Henderson Group Ltd, Man Group PLC, Marshall Wace LLP, Millennium Management LLC, Neuberger Berman Group LLC, PDT Partners LLC, Renaissance Technologies LLC, Schonfeld Strategic Advisors LLC, Squarepoint Ops LLC, T. Rowe Price Associates Inc, Wellington Management Group LLP, and 1 more

How much of the picture this is

A 13F is a manager’s long US-listed equity book at a quarter end, filed up to 45 days later. Buyers and sellers count comparable managers (those that filed both quarters) by shares, so a rise in value with no rise in shares is the price. Large books are listed to their largest positions. These are 95 tracked managers, not the institutional market.

Back to the 13F Explorer →